Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint-Inhibitor Naïve Participants With Advanced or Metastatic Merkel Cell Carcinoma

NCT06947928 is registered in ClinicalTrials.gov with TuHURA Biosciences, Inc. as lead sponsor.

NCT NCT06947928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06947928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint-Inhibitor Naïve Participants With Advanced or Metastatic Merkel Cell Carcinoma
Lead sponsor
TuHURA Biosciences, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
December 11, 2025
Completion date
December 30, 2032
Enrollment
118 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic merkel cell carcinoma